Trial Profile

A compassionate use study of XPro™

Status: Active, no longer recruiting

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 07 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pegipanermin (Primary)
Indications Alzheimer's disease
Focus Expanded access; Therapeutic Use
Sponsors INmune Bio

Most Recent Events

07 May 2024 New trial record
30 Apr 2024 According to an INmune Bio media release, company share an update on two patients from the Phase 1b trial completed in 2021 who have continued to receive XPro™ for treatment of Alzheimers Disease (AD) for more than three years under the Australian compassionate use program known as the Special Access Scheme (SAS).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com